Is Accelerate Diagnostics, Inc. overvalued or undervalued?

As of 3 August 2017, the valuation grade for Accelerate Diagnostics, Inc. moved from does not qualify to risky, indicating a significant change in the company's perceived financial health. The company is currently overvalued, as evidenced by its negative P/E ratio and a price to book value of -0.01. Additionally, the EV to EBITDA stands at -1.51, further highlighting the company's struggles in generating positive earnings.
In comparison to its peers, Accelerate Diagnostics, Inc. shows a stark contrast with Clearpoint Neuro, Inc., which has a P/E ratio of -15.18 and an EV to EBITDA of -15.26, and Stereotaxis, Inc. with a P/E of -7.70 and an EV to EBITDA of -7.49, both of which are also classified as risky. The company's recent performance has been dismal, with a year-to-date return of -99.53% compared to a modest 2.44% return from the S&P 500, reinforcing the notion that it is currently overvalued.